[Studies on platelet aggregation induced by human cultured carcinoma cell lines]. 1984

Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki

Attempts were made to clarify the mechanism of platelet aggregation and to characterize the platelet aggregating material employing established human cancer cell lines. Eleven out of the nineteen human cancer cell lines investigated showed platelet aggregating activity. The existence of divalent cation was required for the platelet aggregation induced by HMV-1 tumor cells. The platelet aggregations induced by tumor cells (HMV-1, PC-10, 3LL) were not suppressed by specific thrombin inhibitor (MD-805). The platelet aggregating activities of tumor cells (HMV-1, M 7609) were diminished by treatment with trypsin but not with collagenase or neuraminidase. Aggregating activity was preserved with a preparation of membrane from these tumor cells, although it was abolished by heating(100 degrees C 15 min) or sonication. By SDS PAGE (autoradiography), membrane proteins with MW of 20,000 daltons which specifically bound to platelets were commonly found in cells with platelet aggregating activity (HMV-1, M 7609), but were absent in platelet non-aggregating cells (HGC-25). It is therefore concluded that platelet aggregation induced by human tumor cells does not require the coexistence of thrombin, but is evoked by direct interaction of platelets with aggregating proteins (MW 20,000 daltons) on the cell membrane.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D009360 Neoplastic Cells, Circulating Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors. Circulating Neoplastic Cells,Embolic Tumor Cells,Embolism, Tumor,Neoplasm Circulating Cells,Tumor Cells, Embolic,Cells, Neoplasm Circulating,Circulating Cells, Neoplasm,Circulating Tumor Cells,Cell, Circulating Neoplastic,Cell, Circulating Tumor,Cell, Embolic Tumor,Cell, Neoplasm Circulating,Cells, Circulating Neoplastic,Cells, Circulating Tumor,Cells, Embolic Tumor,Circulating Neoplastic Cell,Circulating Tumor Cell,Embolic Tumor Cell,Embolisms, Tumor,Neoplasm Circulating Cell,Neoplastic Cell, Circulating,Tumor Cell, Circulating,Tumor Cell, Embolic,Tumor Cells, Circulating,Tumor Embolism,Tumor Embolisms
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D010875 Pipecolic Acids Acids, Pipecolic
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003012 Microbial Collagenase A metalloproteinase which degrades helical regions of native collagen to small fragments. Preferred cleavage is -Gly in the sequence -Pro-Xaa-Gly-Pro-. Six forms (or 2 classes) have been isolated from Clostridium histolyticum that are immunologically cross-reactive but possess different sequences and different specificities. Other variants have been isolated from Bacillus cereus, Empedobacter collagenolyticum, Pseudomonas marinoglutinosa, and species of Vibrio and Streptomyces. EC 3.4.24.3. Clostridiopeptidase A,Clostridium histolyticum Collagenase,Collagenase, Microbial,Collagenase Clostridium histolyticum,Collagenase-Like Peptidase,Collalysine,Nucleolysin,Clostridium histolyticum, Collagenase,Collagenase Like Peptidase,Collagenase, Clostridium histolyticum,Peptidase, Collagenase-Like,histolyticum, Collagenase Clostridium

Related Publications

Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
January 1996, Journal of cancer research and clinical oncology,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
October 1995, Scandinavian journal of gastroenterology,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
January 1982, Progress in clinical and biological research,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
June 1987, Thrombosis research,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
January 1977, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
November 1977, Prostaglandins,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
January 1992, International archives of allergy and immunology,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
August 1992, Clinical and experimental pharmacology & physiology,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
January 1992, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Y Niitsu, and Y Mogi, and K Bannai, and B Ishii, and S Ishigaki, and R Kumai, and Y Koshida, and K Kogawa, and Y Kohgo, and I Urushizaki
December 1972, Acta medicinae Okayama,
Copied contents to your clipboard!